SEOUL (Reuters) – Samsung BioLogics said on Tuesday that it is mass producing COVID-19 antibody treatments developed by Eli Lilly and Co.
The South Korean pharmaceutical contract manufacturer said in a statement that it had signed a manufacturing contract with Eli Lilly in May to address the global demand for COVID-19 treatments.
(Reporting by Joyce Lee; Editing by Jacqueline Wong)
